Described herein is a series of aryl piperazine compounds of the formula: ##STR1## wherein Ar' is a mono or bicyclic aryl or heteroaryl radical substituted with one to three substituents selected from the group consisting of hydrogen, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, (C.sub.1 -C.sub.6)alkylthio, (C.sub.2 -C.sub.6)alkenyl, (C.sub.2 -C.sub.6)alkynyl, (C.sub.1 -C.sub.6)alkylhalo, (C.sub.3 -C.sub.5)cycloalkyl, (C.sub.3 -C.sub.8)cycloalkenyl or halo; R.sup.1 is hydrogen, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, (C.sub.1 -C.sub.6)alkylthio; R.sup.2 is phenyl, naphthyl or (C.sub.3 -C.sub.12)cycloalkyl substituted with one or two substituents selected from the group consisting of hydrogen (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, (C.sub.1 -C.sub.6)alkylthio, (C.sub.2 -C.sub.6)alkenyl, (C.sub.2 -C.sub.6)alkynyl, (C.sub.1 -C.sub.6)alkylhalo, (C.sub.3 -C.sub.8)cycloalkyl, (C.sub.3 -C.sub.8)cycloalkenyl or halo; R.sup.3 is selected from the group consisting of hydrogen (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, (C.sub.1 -C.sub.6)alkylthio, (C.sub.2 -C.sub.6)alkenyl, (C.sub.2 -C.sub.6)alkynyl, (C.sub.1 -C.sub.6)alkylhalo, (C.sub.3 -C.sub.5)cycloalkyl, (C.sub.3 -C.sub.8)cycloalkenyl or halo; X is --(C.dbd.O)--, --CHOH-- or --CH.sub.2 --; or a pharmaceutically acceptable salt, racemate, optical isomer or solvate thereof.

Περιγραμμένη εν τω παρόντι είναι μια σειρά αρυλικών piperazine ενώσεων του τύπου: ## STR1 ## όπου Το AR "είναι ένας μονο ή ποδηλατικός aryl ή heteroaryl ριζοσπάστης που αντικαθίσταται με ένα έως τρία substituents που επιλέγονται από την ομάδα που αποτελείται από το υδρογόνο, (C.sub.1 - C.sub.6)alkyl, (C.sub.1 - C.sub.6)alkoxy, (C.sub.1 - C.sub.6)alkylthio, (C.sub.2 - C.sub.6)alkenyl, (C.sub.2 - C.sub.6)alkynyl, (C.sub.1 - C.sub.6)alkylhalo, (C.sub.3 - C.sub.5)cycloalkyl, (C.sub.3 - C.sub.8)cycloalkenyl ή φωτοστέφανος το R.sup.1 είναι υδρογόνο, (C.sub.1 - C.sub.6)alkyl, (C.sub.1 - C.sub.6)alkoxy, (C.sub.1 - C.sub.6)alkylthio R.sup.2 είναι φαινυλικό, naphthyl ή (C.sub.3 - C.sub.12)cycloalkyl που αντικαθίσταται ένα ή δύο substituents που επιλέγονται με από την ομάδα που αποτελείται από το υδρογόνο (C.sub.1 - C.sub.6)alkyl, (C.sub.1 - C.sub.6)alkoxy, (C.sub.1 - C.sub.6)alkylthio, (C.sub.2 - C.sub.6)alkenyl, (C.sub.2 - C.sub.6)alkynyl, (C.sub.1 - C.sub.6)alkylhalo, (C.sub.3 - C.sub.8)cycloalkyl, (C.sub.3 - C.sub.8)cycloalkenyl ή φωτοστέφανος το R.sup.3 επιλέγεται από την ομάδα που αποτελείται από το υδρογόνο (C.sub.1 - C.sub.6)alkyl, (C.sub.1 - C.sub.6)alkoxy, (C.sub.1 - C.sub.6)alkylthio, (C.sub.2 - C.sub.6)alkenyl, (C.sub.2 - C.sub.6)alkynyl, (C.sub.1 - C.sub.6)alkylhalo, (C.sub.3 - C.sub.5)cycloalkyl, (C.sub.3 - C.sub.8)cycloalkenyl ή φωτοστέφανος Χ είναι -- (C.dbd.O) - -, -- CHOH -- ή -- CH.sub.2 ή ένα φαρμακευτικά αποδεκτό άλας, racemate, ένα οπτικό ισομερές ή solvate επ' αυτού.

 
Web www.patentalert.com

< Compositions and methods to effect the release profile in the transdermal administration of active agents

< Biphasic controlled release delivery system for high solubility pharmaceuticals and method

> Matrix adhering to nasal mucosa

> Piperidine derivatives as serotonine reuptake inhibitors

~ 00095